BERLIN, Germany, April 17, 2025 / Biotech Newswire / --

德国柏林，2025年4月17日 /生物技术新闻社/ --

ProBioGen

ProBioGen

recognizes the significance of the commercial availability of Ziihera® (zanidatamab-hrii), a therapeutic antibody developed using ProBioGen's proprietary

认识到Ziihera®（zanidatamab-hrii）商业上市的重要性，这是一种使用ProBioGen专有技术开发的治疗性抗体，

GlymaxX®

GlymaxX®

technology. In addition, ProBioGen also developed the superior cell line and applied its proprietary media for this antibody. Following FDA approval late last year for the treatment of HER2-positive biliary tract cancer (BTC), this milestone underscores the impact of GlymaxX in advancing innovative biologics and represents a step forward in targeted cancer therapy.

技术。此外，ProBioGen还开发了优良的细胞系并为其抗体应用了专有的培养基。在去年年底获得FDA批准用于治疗HER2阳性胆管癌（BTC）后，这一里程碑突显了GlymaxX在推进创新生物制品方面的影响，并代表了靶向癌症治疗的又一进步。

A GlymaxX modified cell line can be flexibly used to produce differently fucosylated products, depending on the upstream process: In conjunction with fucose-free medium the antibody is literally afucosylated..

一个经过 GlymaxX 改造的细胞系可以灵活用于生产不同岩藻糖基化程度的产品，具体取决于上游工艺：与无岩藻糖的培养基结合使用时，抗体实际上实现了无岩藻糖基化。

'The market availability of a bispecific therapeutic antibody developed with the GlymaxX technology represents an important milestone,'

“利用GlymaxX技术开发的双特异性治疗抗体的市场可用性代表了一个重要的里程碑，”

said Dr. Gabriele Schneider, Chief Business Officer at ProBioGen.

普罗拜奥根公司首席商务官加布里埃勒·施耐德博士说。

'It is rewarding to see our technology play a role in therapies that can make a real difference for patients. We are proud to have contributed to Ziihera's journey by providing our cell line, media, and our proprietary technology to help bring this innovative treatment to market. We look forward to continuing to support groundbreaking advancements in biopharmaceuticals.'.

“看到我们的技术在能够为患者带来真正改变的疗法中发挥作用，这是非常值得的。我们通过提供我们的细胞系、培养基和专有技术，为Ziihera的发展做出了贡献，帮助将这种创新治疗推向市场，我们感到非常自豪。我们期待继续支持生物制药领域的突破性进展。”

As precision medicine continues to evolve, ProBioGen remains dedicated to supporting biopharma innovators through cutting-edge technologies and tailored services that drive therapeutic success - with further GlymaxX-enabled achievements expected in the near future.

随着精准医疗的不断发展，ProBioGen仍致力于通过尖端技术和定制服务支持生物制药创新者取得治疗成功——预计在不久的将来会有更多由GlymaxX技术实现的成果。

Financial details were not disclosed.

财务细节未披露。

For high resolution please click the image.

请单击图像以获得高分辨率。

About

关于

GlymaxX

甘露聚糖酶

ProBioGen developed the GlymaxX® technology to optimize antibody activity, notably the enhanced antibody-mediated cell killing of cancerous or infected cells (known as 'ADCC' activity). GlymaxX is based on the stable introduction of a gene into producer cells that encodes for an enzyme that blocks the cells' fucose biosynthesis pathway and hence the formation of the sugar 'fucose'.

ProBioGen开发了GlymaxX®技术以优化抗体活性，特别是增强抗体介导的癌细胞或受感染细胞的杀伤能力（称为“ADCC”活性）。GlymaxX基于将一个基因稳定导入生产细胞，该基因编码一种酶，能够阻断细胞的岩藻糖生物合成途径，从而抑制糖类“岩藻糖”的形成。

Consequently, in the antibody-producer cells no fucose is added to the antibody's N-linked carbohydrate part. This absence of fucose in antibodies is known to greatly enhance ADCC..

因此，在抗体生产细胞中，没有岩藻糖添加到抗体的N-连接碳水化合物部分。已知抗体中缺乏岩藻糖会大大增强ADCC。

As a unique feature, differentiating it from other approaches, GlymaxX can be applied to both novel or already existing antibody producer cell lines, and entire antibody expression and discovery platforms. GlymaxX does not negatively affect cellular productivity or other product characteristics. Furthermore, a GlymaxX cell line can be flexibly used to produce differently fucosylated products, depending on the upstream process: In fucose-free medium the antibody is literally afucosylated..

作为一种独特的特性，GlymaxX 与其他方法的区别在于，它既可以应用于新型或已有的抗体生产细胞系，也适用于整个抗体表达和发现平台。GlymaxX 不会对细胞生产力或其他产品特性产生负面影响。此外，根据上游工艺的不同，GlymaxX 细胞系能够灵活用于生产不同岩藻糖基化程度的产品：在无岩藻糖的培养基中，抗体实际上会被完全去岩藻糖基化。

The same GlymaxX cell line grown in fucose-containing medium however, uses the provided fucose and produces fully fucosylated antibody. Thus, one GlymaxX cell line can be employed to produce several products: For instance differently fucosylated products, ADCC-enhanced GlymaxX antibodies or wildtype-like, fully fucosylated mAbs, e.

然而，在含有岩藻糖的培养基中生长的相同GlymaxX细胞系会利用所提供的岩藻糖，并产生完全岩藻糖基化的抗体。因此，一个GlymaxX细胞系可以用于生产多种产品：例如，不同岩藻糖基化的产品、ADCC增强型GlymaxX抗体或野生型样、完全岩藻糖基化的单克隆抗体。

g. for a parallel Antibody-Drug-Conjugate (ADC) project. Moreover, GlymaxX has also been used to adjust the fucose level as wanted and by biosimilar-developing companies to match the originators glycoprofile. Overall, GlymaxX is simple, rapid, potent, and universally applicable to different CHO hosts and all other eukaryotic cell species.

g. 用于一个并行的抗体药物偶联物（ADC）项目。此外，GlymaxX还被用于按需调整岩藻糖水平，并被生物类似药开发公司用于匹配原研药的糖谱。总体而言，GlymaxX简单、快速、高效，并且可普遍应用于不同的CHO宿主细胞及所有其他真核细胞种类。

ProBioGen offers its GlymaxX technology royalty-free and non-exclusively as a service or as an individual license..

ProBioGen 免版税且非独家地提供其 GlymaxX 技术作为服务或单独许可。

About

关于

ProBioGen

ProBioGen

ProBioGen is a Berlin-based specialist for developing and manufacturing biopharmaceutical active ingredients, viral vectors and vaccines with applying proprietary technologies to improve product quality and features.

ProBioGen是一家总部位于柏林的公司，专注于开发和生产生物制药活性成分、病毒载体和疫苗，并运用专有技术来提升产品质量和特性。

Combining both state-of-the-art development services, based on ProBioGen's

结合基于ProBioGen的最先进的开发服务，

CHO.RiGHT®

CHO.RiGHT®

expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with optimized properties. Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team.

表达和制造平台，结合智能的特定产品技术，产出具有优化特性的生物制品。快速且集成的细胞系和工艺开发、全面的分析开发以及后续可靠的GMP生产，均由一支高度熟练且经验丰富的团队完成。

All services and technologies are embedded in a total quality management system to assure compliance with GMP standards (EMA/FDA)..

所有服务和技术都嵌入在全面质量管理体系中，以确保符合GMP标准（EMA/FDA）。

ProBioGen has been operational for more than 30 years. At four locations in Berlin, 300 employees contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work. ProBioGen's growth strategy is driven by the expansion of the service value chain through organic growth and potential acquisition.

ProBioGen已经运营了30多年。在柏林的四个地点，300名员工通过他们富有创造力且细致入微的工作，为医学领域的新疗法和全球范围内的突破性创新作出贡献。ProBioGen的增长战略是通过自然增长和潜在收购来扩展服务价值链。

Diversification is a complement driver, while the focus is strict on enabling the development of biopharmaceuticals for tomorrow..

多元化是一个互补的驱动因素，而重点是严格促进未来生物制药的发展。

For more information about ProBioGen, follow us on

想了解更多关于ProBioGen的信息，请关注我们

LinkedIn

领英

.

。

Contacts

联系人

ProBioGen

普罗生物ген

Dr. Gabriele Schneider

加布里埃勒·施耐德博士

Chief Business Officer

首席商务官

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到防垃圾邮件机器人的保护。您需要启用 JavaScript 才能查看它。

ProBioGen Press Contact

ProBioGen新闻联系人

Sarah Wandrey

萨拉·万德雷

Senior Communications Manager

高级传播经理

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到垃圾邮件程序的保护。您需要启用 JavaScript 才能查看它。

Keywords: Drug Discovery; Cell Line; Cell Proliferation; Cell Line Development; Cells, Cultured; Recombinant Proteins; Biological Products; Glycoproteins; Antibodies; Productivity; Antibody-Dependent Cell Cytotoxicity; Fucose; Glycosylation; Technology; Commerce; Germany; GlymaxX®; Antibody; Commercial availability; Cancer therapy; Ziihera®; Zanidatamab-hrii; ProBioGen; Proprietary media; FDA approval; HER2-positive; Biliary tract cancer (BTC); Targeted therapy; Fucosylation; Afucosylated antibody; Bispecific antibody; Dr.

关键词：药物发现；细胞系；细胞增殖；细胞系开发；培养细胞；重组蛋白；生物制品；糖蛋白；抗体；生产力；抗体依赖性细胞毒性；岩藻糖；糖基化；技术；商业；德国；GlymaxX®；抗体；商业可用性；癌症治疗；Ziihera®；Zanidatamab-hrii；ProBioGen；专有培养基；FDA批准；HER2阳性；胆道癌（BTC）；靶向治疗；岩藻糖基化；无岩藻糖基化抗体；双特异性抗体；博士。

Gabriele Schneider; Precision medicine; ADCC (Antibody-Dependent Cellular Cytotoxicity); Fucose biosynthesis; N-linked carbohydrate; Antibody-producer cells; Antibody expression; Cellular productivity; Antibody-Drug Conjugate (ADC); Glycoprofile;CHO.RiGHT® platform.

加布里埃莱·施耐德；精准医疗；ADCC（抗体依赖性细胞毒性）；岩藻糖生物合成；N-连接碳水化合物；抗体生产细胞；抗体表达；细胞生产力；抗体药物偶联物 (ADC)；糖型；CHO.RiGHT® 平台。

Source: Biotech Newswire

来源：生物技术新闻专线